Telomir Pharmaceuticals (NASDAQ: TELO) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for Telomir-Zn, a small-molecule therapeutic candidate designed to treat advanced or metastatic triple-negative breast cancer. The clearance allows the company to initiate a first-in-human Phase 1/2 clinical trial evaluating safety, dosing, and preliminary antitumor activity, supported by preclinical pharmacology, toxicology, and biomarker data.
Triple-negative breast cancer is an aggressive subtype that lacks targeted treatment options, often resulting in poor prognosis. The IND clearance is a critical milestone for Telomir Pharmaceuticals as it transitions from preclinical to clinical development. According to the company, Telomir-Zn modulates intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. These mechanisms are implicated in cancer, aging, and degenerative disease, positioning Telomir-Zn as a potential first-in-class therapy.
The clinical trial will enroll patients with advanced or metastatic triple-negative breast cancer who have limited treatment options. If successful, Telomir-Zn could address a significant unmet medical need. The FDA's acceptance of the IND application indicates that preclinical data were sufficient to support moving forward, though the drug's efficacy and safety remain unproven in humans.
Telomir Pharmaceuticals is a clinical-stage biotechnology company focused on developing small-molecule therapeutics. Its lead program, Telomir-1 (Telomir-Zn), has shown activity in preclinical studies. The company's newsroom provides the latest updates at https://ibn.fm/TELO. For more details on the press release, visit https://ibn.fm/p4e9J.
The clearance comes at a time when the biotech industry is actively seeking novel approaches to hard-to-treat cancers. Telomir's focus on epigenetic and metabolic pathways reflects a broader trend toward targeting fundamental cellular processes. Investors and industry observers will watch the upcoming trial results closely, as positive data could significantly impact the treatment landscape for triple-negative breast cancer and potentially other indications.
